

July 18, 2025

The General Manager,
Department of Corporate Services,
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 506943

Ref: Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015

Sub: Scheme of amalgamation of J.B. Chemicals & Pharmaceuticals Limited ("Transferor Company") with Torrent Pharmaceuticals Limited ("Transferee Company") and their respective shareholders ("Scheme"/ "Scheme of Amalgamation")

Dear Sir / Ma'am,

In connection with the Scheme involving the amalgamation of Transferor Company with the Transferee Company, and their respective shareholders, in accordance with Sections 230 to 232 of the Companies Act, 2013 and other applicable laws, we hereby confirm, in light of Part I(A)(2)(b) and Part I(A)(2)(j) of the Securities and Exchange Board of India issued Master Circular dated 20 June 2023 (bearing reference number: SEBI/HO/CFD/POD-2/P/CIR/2023/93) (and all amendments thereto) and as required per the checklist by BSE Limited:

- a) No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with BSE Limited and the National Stock Exchange of India Limited and period under consideration for valuation.
- b) There are no past defaults of listed debt obligations of the Transferor Company forming part of the Scheme.

For J.B. Chemicals & Pharmaceuticals Limited

MUMBA

Sandeep Phadnis

Vice President - Secretarial

& Company Secretary.

Membership No.: A11530



July 18, 2025

To.

National Stock Exchange of India Limited 'Exchange Plaza'. C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051

Symbol: JBCHEPHARM

Ref: Regulation 37 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015

Sub: Scheme of amalgamation of J.B. Chemicals & Pharmaceuticals Limited ("Transferor Company") with Torrent Pharmaceuticals Limited ("Transferee Company") and their respective shareholders ("Scheme"/ "Scheme of Amalgamation")

Dear Sir / Ma'am,

In connection with the Scheme involving the amalgamation of Transferor Company with the Transferee Company, and their respective shareholders and creditors, in accordance with Sections 230 to 232 of the Companies Act, 2013 and other applicable laws, we hereby confirm, in light of Part I(A)(2)(b) and Part I(A)(2)(j) of the Securities and Exchange Board of India issued Master Circular dated 20 June 2023 (bearing reference number: SEBI/HO/CFD/POD-2/P/CIR/2023/93) (and all amendments thereto) and as required per the checklist by BSE Limited:

- a) No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with BSE Limited and the National Stock Exchange of India Limited and period under consideration for valuation.
- b) There are no past defaults of listed debt obligations of the Transferor Company forming part of the Scheme.

For J.B. Chemicals & Pharmaceuticals Limited

Sandeep Phadnis

Vice President – Secretarial & Company Secretary

Membership No. A11530

Hhadys

